Observational Study Evaluating Long-term Health Outcomes of Canadian DUODOPA-treated Patients

AbbVie

Status: Completed

Conditions: Parkinson Disease (PD)

Study type: Observational

Funder types: Industry

Identifiers

NCT02485600

P14-506

Details and patient eligibility

About

This is an open-label, postmarketing, observational study to document health outcomes, in Canadian patients with advanced Parkinson's disease and long-term treatment with Duodopa (levodopa/carbidopa intestinal gel).

Enrollment: 88 patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed with advanced Parkinson's Disease
• Prescribed Duodopa by his/her treating physician.

Exclusion criteria

• Patients who were previously treated with Duodopa.
• Presence of other condition that, in the opinion of the treating physician, prohibits the patient from participating in the study or obscures the assessment of the treatment of advanced PD.

Trial design

88 participants in 1 patient group

DUODOPA patients.

Description:

Patients starting DUODOPA treatment at time of enrollment.